№ п./п.	Название исследования	Год
Ссылка		
1	**Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines**	2020
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248264/		
2	**Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine a dose-escalation, open-label, non-randomised, first-in-human trial**	2020
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext		
3	**Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial**	2020
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext		
4	**A Bivalent Human Adenovirus Type 5 Vaccine Expressing the Rabies Virus Glycoprotein and Canine Distemper Virus Hemagglutinin Protein Confers Protective Immunity in Mice and Foxes**	2020
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309451/		
5	**Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption**	2020
https://www.nature.com/articles/s41591-020-0774-y		
6	**Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses**	2020
https://www.biorxiv.org/content/10.1101/2020.07.30.227470v1		
7	**The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism**	2020
https://www.biorxiv.org/content/10.1101/2020.07.20.213223v1		
8	**Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice**	2020
https://www.nature.com/articles/s41541-020-0200-y		
9	**Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein**	2019
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475872/		
10	**State-of-the-art human adenovirus vectorology for therapeutic approaches**	2019
https://pubmed.ncbi.nlm.nih.gov/31758807/		
11	**Human adenovirus type 26 uses sialic acid–bearing glycans as a primary cell entry receptor**	2019
https://advances.sciencemag.org/content/5/9/eaax3567		
12	**Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs**	2019
https://www.sciencedirect.com/science/article/pii/S0264410X19312307		
13	**Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates**	2018
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056916/		

14	**Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge**	2018
https://pubmed.ncbi.nlm.nih.gov/30142207/		
15	**Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys**	2018
https://pubmed.ncbi.nlm.nih.gov/29793950/		
16	**First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector**	2018
https://pubmed.ncbi.nlm.nih.gov/29669026/		
17	**Heterologous prime–boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus**	2018
https://pubmed.ncbi.nlm.nih.gov/29739720/		
18	**Разработка вакцин на основе аденовирусных векторов: обзор зарубежных клинических исследований (Часть 1)**	2017
https://www.mimmun.ru/mimmun/article/view/1216		
19	**Разработка вакцин на основе аденовирусных векторов: обзор зарубежных клинических исследований (Часть 2)**	2017
https://www.mimmun.ru/mimmun/article/view/1307		
20	**Векторные вакцины против болезни,вызванной вирусом Эбола**	2017
https://cyberleninka.ru/article/n/vektornye-vaktsiny-protiv-bolezni-vyzvannoy-virusom-ebola		
21	**Safety profile of a replication-deficient human adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle**	2017
https://pubmed.ncbi.nlm.nih.gov/29076657/		
22	**Recent advances in genetic modification of adenovirus vectors for cancer treatment**	2017
https://pubmed.ncbi.nlm.nih.gov/28266780/		
23	**32 - Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective**	2016
https://www.sciencedirect.com/book/9780128002766/adenoviral-vectors-for-gene-therapy		
24	**Adenoviral vector-based strategies against infectious disease and cancer**	2016
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994731/#:~:text=and%20Dongming%20Zhou-,ABSTRACT,genetically%20modified%20for%20cancer%20therapy.		
25	**First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens**	2016
https://pubmed.ncbi.nlm.nih.gov/28077588/		
26	**IMMUNOBIOLOGICAL DRUG AND METHOD FOR USING SAME FOR INDUCING SPECIFIC IMMUNITY AGAINST THE EBOLA VIRUS**	2016
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016130047		
27	**Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats**	2015
https://pubmed.ncbi.nlm.nih.gov/26319741/		

28	**High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial**	2015
https://pubmed.ncbi.nlm.nih.gov/26333337/		
29	**Ad35.CS.01-RTS,S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy Malaria-Naïve adults**	2015
https://pubmed.ncbi.nlm.nih.gov/26148007/		
30	**Induction of HIV-1–specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans**	2015
https://pubmed.ncbi.nlm.nih.gov/25165165/		
31	**A Phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of electroporated HIV DNA with or without interleukin 12 in prime-boost combinations with an Ad35 HIV vaccine in healthy HIV-seronegative african adults**	2015
https://pubmed.ncbi.nlm.nih.gov/26252526/		
32	**A Phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults**	2015
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141687		
33	**Immunization with Hexon Modified Adenoviral Vectors Integrated with gp83 Epitope Provides Protection against Trypanosoma cruzi Infection**	2014
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003089		
34	**First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)**	2014
https://pubmed.ncbi.nlm.nih.gov/24719474/		
35	**Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial**	2014
https://pubmed.ncbi.nlm.nih.gov/25007091/		
36	**A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity**	2013
https://pubmed.ncbi.nlm.nih.gov/24089406/		
37	**Viral vectors for vaccine applications**	2013
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710930/		
38	**Using Multivalent Adenoviral Vectors for HIV Vaccination**	2013
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0060347		
39	**Interleukin-Encoding Adenoviral Vectors as Genetic Adjuvant for Vaccination against Retroviral Infection**	2013
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0082528		
40	**Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans, Vaccine**	2013
https://pubmed.ncbi.nlm.nih.gov/23357198/		
41	**Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum. Vaccin**	2013

https://pubmed.ncbi.nlm.nih.gov/23899517/		
42	**A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age**	2013
https://pubmed.ncbi.nlm.nih.gov/24244339/		
43	**First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine**	2013
https://pubmed.ncbi.nlm.nih.gov/23125444/		
44	**DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity**	2013
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0055571		
45	**Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans**	2013
https://www.sciencedirect.com/science/article/pii/S0264410X13000807		
46	**Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species**	2012
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0044115		
47	**Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man**	2012
https://pubmed.ncbi.nlm.nih.gov/22218690/		
48	**Advances and future challenges in recombinant adenoviral vectored h5n1 influenza vaccines**	2012
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509669/		
49	**Adenovirus 5-vectored P.falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults**	2011
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0024586		
50	**A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)**	2011
https://pubmed.ncbi.nlm.nih.gov/21857901/		
51	**The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert**	2010
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3067347/		
52	**Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Response**	2010
https://pubmed.ncbi.nlm.nih.gov/20126394/		
53	**Protective Efficacy and Immunogenicity of an Adenoviral Vector Vaccine Encoding the Codon-Optimized F Protein of Respiratory Syncytial Virus**	2009
https://jvi.asm.org/content/83/23/12601		
54	**Advanced Malignant Pleural orPeritoneal Effusion in Patients Treatedwith Recombinant Adenovirus p53Injection plus Cisplatin**	2008
https://pubmed.ncbi.nlm.nih.gov/19094436/		

55	**Adenoviruses: Malignant Transformation and Oncology**	2008
https://www.sciencedirect.com/science/article/pii/B9780123744104003575		
56	**Adenovirus 5 and 35 vectors expressingPlasmodium falciparumcircumsporozoite surface protein elicit potent antigen-specificcellular IFN-and antibody responses in mice**	2008
https://www.sciencedirect.com/science/article/pii/S0264410X08004180		
57	**A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults, Vaccine**	2008
https://pubmed.ncbi.nlm.nih.gov/18448211/		
58	**Role of MyD88 and TLR9 in the Innate Immune ResponseElicited by Serotype 5 Adenoviral Vectors**	2007
https://pubmed.ncbi.nlm.nih.gov/17685831/		
59	**Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine**	2007
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077857/		
60	**Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity**	2006
https://pubmed.ncbi.nlm.nih.gov/16963747/		
61	**Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity**	2005
https://pubmed.ncbi.nlm.nih.gov/19559110/		
62	**Adenoviral vectors: a promising tool for gene therapy**	2005
https://pubmed.ncbi.nlm.nih.gov/16622281/		
63	**Good Manufacturing Practice Production of Adenoviral Vectors for Clinical Trials**	2005
https://pubmed.ncbi.nlm.nih.gov/15812223/		
64	**Gene therapy clinical trials worldwide 1989–2004—an overview**	2004
https://onlinelibrary.wiley.com/doi/10.1002/jgm.619		
65	**Adenoviruses as Vaccine Vectors**	2004
https://www.sciencedirect.com/science/article/pii/S1525001604013425		
66	**Safety of Adenoviral Vectors: Results ofClinical Investigations in 445 Cancer PatientsTreated with Advexin® (Adenoviral p53) GeneTherapy**	2004
https://cyberleninka.org/article/n/1336451		
67	**Adenoviral vectors for gene transfer and therapy**	2004
https://onlinelibrary.wiley.com/doi/abs/10.1002/jgm.496		
68	**Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins**	2004
https://jvi.asm.org/content/79/2/771		
69	**Immunogenicity of Recombinant Adenovirus Serotype 35Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity**	2004
https://pubmed.ncbi.nlm.nih.gov/15128818/		

70	**Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission**	2004
https://www.nature.com/articles/7700765		
71	**Production of adenovirus vector for gene therapy**	2002
https://pubmed.ncbi.nlm.nih.gov/14550017/		
72	**Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response**	2002
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459421/		
73	**A New Vector System with Inducible E2a Cell Line for Production of Higher Titer and Safer Adenoviral Vectors**	2000
https://pubmed.ncbi.nlm.nih.gov/10998335/		
74	**Human adenovirus type 5 vectors expressing rabies glycoprotein**	1996
https://www.sciencedirect.com/science/article/pii/S0264410X96000126		
75	**Adenovirus vectors as recombinant viral vaccines**	1995
https://www.sciencedirect.com/science/article/pii/0264410X9500032V#:~:text=Adenoviruses%20can%20efficiently%20induce%20immunity,have%20been%20constructed%20and%20tested.		
76	**Gene therapy using adenoviral vectors**	1994
https://www.sciencedirect.com/science/article/abs/pii/0958166994900841		
77	**Adenoviruses as expression vectors and recombinant vaccines**	1990
https://pubmed.ncbi.nlm.nih.gov/1366528/		